Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for posting this. We should be worth $6B. Give it to us soon, por favor.
Lol!!! You honestly have to laugh at this shit.
Touché!!
Wow, there’s some non-compelling data out there, but this takes the cake.
Shoot me an e-mail to mikemiller335095@yahoo.com
Can you please confirm that your source is not someone who has ever posted on this board?
Thanks. What an absolute dumpster fire. Has a similar feel to JZ dumping in January '20 ahead of Reno. i.e. What don't we know?
Don't disagree with Onerag that they could dilute and try to launch some other formulation/product. This company is delusional at every level.
Obi Wan (Denner).....you're our only hope.....
I've been traveling the past few weeks. Did Eckman have a Form 4 that I missed where he sold all of his shares?
Tell that to the Sheroes! I bet they'd disagree!
Best representation that Amarin has ever had. That was simply brilliant. Here’s to Newman being persuasive.
And speaking of AMRN, fuck them for having a 1-drug company and being completely unprepared to defend their patent in Nevada.
Marjac > Singer
Thx for sharing. Would have been surprised to hear anything other. They should slim to 50 employees until BO and save another $100M of cash.
Give us our $6B Alex!!!
Yeah, just like I should believe:
- 800 salespeople can sell Vascepa
- Amarin can grow the market faster then generics
- Generics won't be able to grow their market share due to supply
- "We'd be offended if there weren't any ANDA filers" -Thero quote
- China approval should come by the end of 2021
- We're very confident in our IP and have over 100 patents on Vascepa
I can go on, but this company is horrible at operating. What you'd think you can believe, you can't. And what you'd expect them to be prepared for, they aren't.
Only thing to do in the US (as long as AMRN is around) is authorized generic when it makes sense. If there's ever a combo pill, it won't be Amarin bringing it to market. Could you imagine a dilution, serious dive into combo-pill R&D and no Denner? We'd trade at $1.25 for 3 years until EU revs ramp up.
Bring us home Alex!!! $6B baby!!!
It’s pretty dumb. I traded messages with Jonathan Rowe about 2 years ago - the guy who’s name is on many V patents. He said there’s serious engineering challenges to create the combo pill. Do you really want Amarin pissing away another $200M on R&D? Jesus, what a nightmare.
He’s the lead wolf in the wolf pack. Guessing he’s got a lot of support from mutual funds and other institutions already. I did also send him a note mentioning we could easily get another 2-3M shares of support from retail to support their maximizing of sh value. Doubt he ever needs that though.
I do agree with whoever said it.....odd that BB just sat on their ass for the past 2 years during this mismanagement shitshow.
Given AMRN’s position with clock ticking in EU and no shot at commercializing on their own, I’d expect Sarissa’s time frame to be on the shorter end here. Unlike other companies, there’s not much else here to maximize shareholder value other than a BO. Seems reasonable to expect action in late 2022.
Reduce-It patent holes poked. Stock heads to the 2s.
I mean....it's $40k, but the man was brilliant in Jan 2020 going "risk-off" and probably knew the patents better than anyone at Amarin. Clearly a positive omen.
Chas - still waiting on your “last of the seemingly endless opportunities to buy before we moon” posts. Please….just for old time’s sake?
I really need a final Chas message regarding the final of a seemingly endless number of opportunities to add before this baby moons. Chas123 can you please accommodate us? TIA
MDCO was trading around $16/share 12 months before they were bought out at $85/share.
Yep, definitely a positive catalyst. If we weren't all so jaded, this would probably be a good cue to buy more shares.
By share count is 100% irrelevant. $30M is chump change to this guy, but that being said, he doesn't have a lot of positions, so obviously believes there's value here. Hopefully it's near term value.
$12 These guys can't wait forever.
You are much more bullish on the ROW roll-out than I. At "Amarin speed", getting to $1B of ROW sales is probably a 5 year endeavor.
Haha, you're ineffective.
Imagine being presented with the following opportunity on 9/15/2018:
- You can buy AMRN shares at $4/share on 11/5/21
- Reduce-It is an absolute smashing success! Best CVD data since statins.
- ADCOMM occurs, but Vascepa gets 16-0 positive vote!
- FDA approves broad label in late 2019
- EU approves broad label in early 2021
- China broad CVD label likely coming in next 60 days.
That's how fucked the execution here has been. Pretty unreal.
Same 3,000 more at $4.20.
Yep, we're all just sitting on call options for the buyout now. EU rollout is gonna be slow and disappointing, IMO.
Shitty investment thesis, yet here we all are! :) :) :)
Yeah, that certainly doesn't hurt, but they're also likely being acquired. It is OT, but it's also an example of how Amarin should have played this....sell to the highest bidder without assuming execution risk (including patent defense).....
AUPH has played their trial results perfectly.
You would be shocked and disappointed how little the $5 share price has to do with manipulation and pinning.
JL wasn’t the indicator to sell. It was JZ, who knew the vulnerability of the Marine patents probably more than anyone else. He unloaded like a mother in early Jan ‘20 I believe.
I bought more at $18.xx and will never buy another share of this POS operation.
Lol, lumped in with cocoa! This should really ignite the PPS! :) :)
Yep, down to 15,000 hours per week dedicated to ONE drug. ONE!! Hopefully the 300 Amarin kept are savvy in digital marketing.
Has anyone seen a commercial lately? I haven’t seen one in months.
The right move, but frustrating how non-agile this company has been prior to KM. If we had declining scripts with 600-800 sales reps, I’d argue that the cuts didn’t go far enough. I suppose they want to preserve some semblance of a sales team in the event the infringement case goes our way.
How many 1-drug companies exist that are selling $600M annually? Just one, I believe…..
The only shade we'll be is 50 shades of red on Monday.
This thing is going to drop like a fu@king rock to $4 on Monday. I’m shorting this biotch so hard on Friday. I’m also telling my employer that I want to work forever because I just absolutely love my client service job and would like to work for another 30 years in that capacity.
There, I did. Taking the complete opposite position of Nov 2018.